Boston Scientific has announced that its cardiac resynchronisation therapy defibrillators (CRT-D) devices powered by EnduraLife battery technology have earned a recommendation from the UK's National Institute for Health and Care Excellence (NICE).
The regulator has endorsed the routine use of EnduraLife-powered CRT-Ds for treating NHS patients with heart failure in England and Wales, based on the clinical benefits and cost savings the technology can provide.
“Boston Scientific's EnduraLife-powered cardiac resynchronisation therapy defibrillators have earned a recommendation from NICE.“
NICE's evaluation concluded that the extended battery life observed with EnduraLife will reduce the number of avoidable replacement procedures a patient may have to undergo, leading to improved outcomes and potential savings to the NHS in England of approximately six million pounds in the first five years.
EnduraLife battery technology offers nearly twice the usable battery capacity as competing devices, while the CRT-D units themselves are up to 18 percent smaller. The technology was first launched in 2008.
Dr Kenneth Stein, senior vice-president and chief medical officer for global health policy and rhythm management at Boston Scientific, said: "We are proud to have our EnduraLife Battery Technology recognised by NICE's evidence-based review process and available for the benefit of patients and the healthcare system at large."
With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.See all the latest jobs in Medical Devices